Viking Therapeutics is trading 5.2% down today at $39.01 amid profit-taking and normal biotech volatility following recent gains.
- No fresh company-specific headlines, FDA decisions, or earnings releases have been reported as of July 10, 2026, to explain the downward move.
- The stock is giving back a portion of last week's sharp gains, which were driven by positive developments in the company's obesity drug pipeline earlier this year.